Syndax Pharmaceuticals (SNDX) Short-term Investments (2015 - 2026)

Syndax Pharmaceuticals' Short-term Investments history runs 12 years deep, the most recent figure standing at $221.2 million for Q1 2026.

• In Q1 2026, Short-term Investments rose 5273.45% year-over-year to $221.2 million; the TTM figure through Mar 2026 stood at $221.2 million (up 5273.45% YoY), while the FY2025 annual figure was $19.6 million, up 95.59% from the prior year.
• Short-term Investments for Q1 2026 stood at $221.2 million, up from $19.6 million in the prior quarter.
• The five-year high for Short-term Investments was $401.4 million in Q4 2022, with the low at $4.1 million in Q1 2025.
• The 5-year median for Short-term Investments is $18.2 million (2025), against an average of $124.4 million.
• The sharpest annual moves came in 2022 and 2025: Short-term Investments soared 348983.48% in 2022, then plunged 98.71% in 2025.
• Syndax Pharmaceuticals' Short-term Investments stood at $401.4 million in 2022, then plunged by 31.42% to $275.3 million in 2023, then sank by 96.36% to $10.0 million in 2024, then surged by 95.59% to $19.6 million in 2025, then soared by 1027.5% to $221.2 million in 2026.
• Business Quant data shows SNDX's Short-term Investments at $221.2 million in Q1 2026, $19.6 million in Q4 2025, and $18.2 million in Q3 2025.